Raymond James Has Lowered Expectations for DRI Healthcare Trust (TSE:DHT.UN) Stock Price

DRI Healthcare Trust (TSE:DHT.UN) had its price objective cut by Raymond James from C$23.00 to C$22.00 in a note issued to investors on Wednesday,BayStreet.CA reports. Raymond James’ price objective suggests a potential upside of 68.84% from the company’s previous close.

Several other research analysts have also commented on the company. Truist Financial dropped their price target on DRI Healthcare Trust from C$17.00 to C$14.00 in a research report on Thursday, July 25th. Scotiabank lifted their target price on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of C$18.00.

DRI Healthcare Trust Price Performance

Shares of TSE:DHT.UN opened at C$13.03 on Wednesday. The firm has a fifty day simple moving average of C$13.30 and a two-hundred day simple moving average of C$13.63. DRI Healthcare Trust has a 52 week low of C$10.39 and a 52 week high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.